Chronic Kidney Disease

October 23, 2020

The gout treatment allopurinol doesn't appear to slow the progression of chronic kidney disease in patients with moderate to severe loss of kidney function, shows a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

October 23, 2020

Treatments for lupus nephritis can cost patients over $50,000 a year, according to a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

October 02, 2020

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

December 19, 2018

Canadian researchers looked at the safety of short-term use in patients with hypertension, heart failure, or chronic kidney disease.

November 28, 2018

British researchers build a strong case for closer monitoring of renal function in patients with gout.

November 21, 2016

Allopurinol is not associated with an increased risk of renal function deterioration, a study presented at ACR 2016 shows.

November 21, 2016

Allopurinol is not associated with an increased risk of renal function deterioration, a study presented at ACR 2016 shows.